Molecular Research of Triple-Negative Breast Cancer

Dear Colleagues,

Breast cancer is classified on the basis of histological and molecular variability; a subgroup equally heterogeneous is triple-negative breast cancer (TNBC), which shows lost expression of PR, ER and HER2/NEU receptors and a general molecular expression that confers it a particularly metastatic and invasive nature, drug resistance and poor prognosis. Therefore, several subtypes that actually have no specific molecular targets characterize TNBC and, consequently, a feature that makes it difficult to set a valid therapeutic strategy and so, to date, conventional chemotherapy is the only choice.

The Special Issue, entitled “Molecular Research of Triple-Negative Breast Cancer”, aims to collect recent results in this context, as:

• Genetic, epigenetic, transcriptional profiles;
• Description of proteomic features and/or biochemical pathways;
• Identification of cancer stem cells and their cross-talk with microenvironment; metabolic reprogramming;
• Effect induced in vitro/in vivo of any (or combination of) drugs;
• Triple-negative breast cancer immunity and metabolic reprogramming;
• Any evidence useful to suggest and define novel molecular target to challenge the aggressive character of TNBC.

Dr. Anna De Blasio
Dr. Daniela Carlisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.